Overview

Oxazyme in Patients With Hyperoxaluria

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
0
Participant gender:
All
Summary
Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be increased. Both effects would decrease blood levels of oxalate, and hence oxalate excretion in the urine.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
OxThera
Criteria
Inclusion Criteria:

- Roux-en-Y gastric bypass hyperoxaluric Calcium oxalate (CaOx) stone subjects or
Idiopathic hyperoxaluric CaOx stone subjects

- Patients must have or had radio-opaque stones present on x-ray, or a history
consistent with the passage of a stone or stone surgery or Extracorporeal Shock Wave
Lithotripsy (ESWL) in the last 5 years.

- Hyperoxaluria Ox/Cr ratio ≥36 mg/g

- The patient must be able to provide written informed consent

- Patients must be able to urinate reliably into a collection vessel to measure urine
volume.

- Patients may be taking drugs for the prevention of stone disease, including
pyridoxine, thiazides, citrate supplements and allopurinol, as long as there have been
no changes in these medications for at least 3 months

Exclusion Criteria:

- Primary hyperoxaluria patients

- Use of Oxadrop, Oxabsorb, or other therapies affecting oxalate absorption from the
gut, other than stable doses of calcium.

- Subjects who are pregnant. Women of childbearing potential must have a negative
pregnancy test prior to enrollment and must practice some form of birth control during
the trial.

- Patients on an unstable dose of any other drugs for the prevention of stone disease
(i.e., pyridoxine, citrate supplements. etc.). Patients should have been on a stable
dose for at least 3 months prior to randomization.